BioLineRx (NASDAQ: BLRX) CFO reports extensive stock option grants and shares

Rhea-AI Filing Summary

BioLineRx Ltd. chief financial officer Zeevi Mali filed an initial ownership report listing his equity position in the company. The filing shows multiple employee stock option grants over several years under the 2003 Amended and Restated Share Incentive Plan, alongside direct holdings of 1,311,000 Ordinary Shares.

The disclosed options cover underlying Ordinary Shares at exercise prices ranging from $0.0060 to $0.2870, with expiration dates between 2026 and 2035. Earlier grants from 2016 through 2022 are fully vested, while a grant dated March 21, 2023 is partly vested and continues to vest quarterly, and a large grant dated November 19, 2025 had no vested options initially and will vest over a one-year cliff and then 12 quarterly installments, subject to continued service. Certain securities tied to the plan are required to be registered in the name of a trustee to qualify for Israeli tax benefits.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Zeevi Mali

(Last) (First) (Middle)

BIOLINERX LTD.

2 HAMA'AYAN STREET

(Street)

MODII'N 7177871

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioLineRx Ltd. [ BLRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares, 0.1 NIS per share	1,311,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)	10/09/2017	10/09/2026	Ordinary Shares	43,800(10)	$0.264	D
Employee Stock Option (Right to Buy)(1)(3)	02/21/2018	02/21/2027	Ordinary Shares	126,600(10)	$0.27	D
Employee Stock Option (Right to Buy)(1)(4)	12/26/2018	12/26/2027	Ordinary Shares	280,200(10)	$0.287	D
Employee Stock Option (Right to Buy)(1)(5)	03/25/2020	03/25/2029	Ordinary Shares	454,800(10)	$0.276	D
Employee Stock Option (Right to Buy)(1)(6)	11/17/2021	11/17/2030	Ordinary Shares	704,400(10)	$0.15	D
Employee Stock Option (Right to Buy)(1)(7)	03/15/2023	03/15/2032	Ordinary Shares	1,006,800(10)	$0.101	D
Employee Stock Option (Right to Buy)(1)(8)	03/21/2024	03/21/2033	Ordinary Shares	1,078,800(10)	$0.045	D
Employee Stock Option (Right to Buy)(1)(9)	11/19/2026	11/19/2035	Ordinary Shares	13,680,000(10)	$0.006	D

Explanation of Responses:

1. Options granted under the 2003 Amended and Restated Share Incentive Plan.

2. The grant date of this grant is October 9, 2016. This option grant is fully vested as of this date.

3. The grant date of this grant is February 21, 2017. This option grant is fully vested as of this date.

4. The grant date of this grant is December 26, 2017. This option grant is fully vested as of this date.

5. The grant date of this grant is March 25, 2019. This option grant is fully vested as of this date.

6. The grant date of this grant is November 17, 2020. This option grant is fully vested as of this date.

7. The grant date of this grant is March 15, 2022. This option grant is fully vested as of this date.

8. The grant date of this grant is March 21, 2023. As of this date, 741,600 of the options were vested as of the date of appointment. The remaining 337,200 options will vest in 5 equal quarterly installments, subt to the Reporting Person's continued service to the Issuer as of each vesting date.

9. The grant date of this grant is November 19, 2025. As of this date, none of the options were vested. As of the grant date 3,420,000 options have a one-year cliff and the remaining 10,260,000 options will vest in 12 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

10. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

	/s/ Mali Zeevi	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does BioLineRx (BLRX) CFO Zeevi Mali report in this Form 3?

Zeevi Mali reports his initial ownership in BioLineRx, including multiple employee stock option grants and 1,311,000 Ordinary Shares. The options span several grant years, exercise prices, and expiration dates, outlining his long-term equity-based compensation and potential future share ownership.

How many BioLineRx Ordinary Shares does the CFO directly hold?

The filing lists direct ownership of 1,311,000 Ordinary Shares of BioLineRx Ltd. This is separate from his various employee stock options, which, if exercised, could increase his overall equity exposure beyond these already held Ordinary Shares.

What stock option grants are disclosed for the BioLineRx (BLRX) CFO?

The CFO discloses several employee stock option grants under the 2003 Amended and Restated Share Incentive Plan, with exercise prices from $0.0060 to $0.2870 and expiration dates between 2026 and 2035, each covering a specified number of underlying Ordinary Shares.

Which BioLineRx CFO option grants are already fully vested?

Option grants with grant dates of October 9, 2016, February 21, 2017, December 26, 2017, March 25, 2019, November 17, 2020, and March 15, 2022 are described as fully vested, meaning all related options are currently exercisable under their respective terms.

How do the March 2023 and November 2025 BioLineRx option grants vest for the CFO?

The March 21, 2023 grant has 741,600 options vested at appointment, with 337,200 vesting in five equal quarterly installments. The November 19, 2025 grant has a one-year cliff on 3,420,000 options, while 10,260,000 vest in 12 equal quarterly installments, conditional on continued service.

Why are some BioLineRx CFO plan securities registered in a trustee’s name?

To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee under the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee, rather than directly in the employee’s name.